140 related articles for article (PubMed ID: 21044751)
1. Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials.
Zhang L; Zhang S; Jiang H; Sun A; Wang Y; Zou Y; Ge J; Chen H
Arch Med Res; 2010 Aug; 41(6):464-71. PubMed ID: 21044751
[TBL] [Abstract][Full Text] [Related]
2. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure.
Sola S; Mir MQ; Rajagopalan S; Helmy T; Tandon N; Khan BV
J Card Fail; 2005 Oct; 11(8):607-12. PubMed ID: 16230264
[TBL] [Abstract][Full Text] [Related]
3. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Bleske BE; Nicklas JM; Bard RL; Brook RD; Gurbel PA; Bliden KP; Rajagopalan S; Pitt B
J Am Coll Cardiol; 2006 Jan; 47(2):338-41. PubMed ID: 16412857
[TBL] [Abstract][Full Text] [Related]
4. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
Mozaffarian D; Minami E; Letterer RA; Lawler RL; McDonald GB; Levy WC
Am J Cardiol; 2005 Dec; 96(12):1699-704. PubMed ID: 16360360
[TBL] [Abstract][Full Text] [Related]
5. Neurohumoral and inflammatory activation in patients with coronary artery disease treated with statins.
Van de Veire NR; Philippé J; De Winter O; Langlois M; Bernard D; De Sutter J
Heart; 2006 Dec; 92(12):1858-9. PubMed ID: 17105891
[No Abstract] [Full Text] [Related]
6. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
[TBL] [Abstract][Full Text] [Related]
7. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis.
Tikiz C; Utuk O; Pirildar T; Bayturan O; Bayindir P; Taneli F; Tikiz H; Tuzun C
J Rheumatol; 2005 Nov; 32(11):2095-101. PubMed ID: 16265685
[TBL] [Abstract][Full Text] [Related]
8. Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure.
Tekin A; Sezgin N; Katircibaşi MT; Tekin G; Cölkesen Y; Sezgin AT; Müderrisoğlu H
Coron Artery Dis; 2008 Nov; 19(7):513-9. PubMed ID: 18923248
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
Castro PF; Miranda R; Verdejo HE; Greig D; Gabrielli LA; Alcaino H; Chiong M; Bustos C; Garcia L; Mellado R; Vukasovic JL; Godoy I; Lavandero S
J Heart Lung Transplant; 2008 Apr; 27(4):435-41. PubMed ID: 18374881
[TBL] [Abstract][Full Text] [Related]
10. Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.
Anker SD; Clark AL; Winkler R; Zugck C; Cicoira M; Ponikowski P; Davos CH; Banasiak W; Zardini P; Haass M; Senges J; Coats AJ; Poole-Wilson PA; Pitt B
Int J Cardiol; 2006 Sep; 112(2):234-42. PubMed ID: 16846656
[TBL] [Abstract][Full Text] [Related]
11. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
12. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure.
Gürgün C; Ildizli M; Yavuzgil O; Sin A; Apaydin A; Cinar C; Kültürsay H
Int J Cardiol; 2008 Jan; 123(2):102-7. PubMed ID: 17320212
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of statins in patients with non-ischemic heart failure.
Laufs U; Wassmann S; Schackmann S; Heeschen C; Böhm M; Nickenig G
Z Kardiol; 2004 Feb; 93(2):103-8. PubMed ID: 14963675
[TBL] [Abstract][Full Text] [Related]
14. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure.
May HT; Muhlestein JB; Carlquist JF; Horne BD; Bair TL; Campbell BA; Kfoury AG; Lyon JL; Kim H; Renlund DG
Am J Cardiol; 2006 Sep; 98(5):653-8. PubMed ID: 16923455
[TBL] [Abstract][Full Text] [Related]
15. Statin use in heart failure: a cause for concern?
Raina A; Pickering T; Shimbo D
Am Heart J; 2006 Jul; 152(1):39-49. PubMed ID: 16824830
[TBL] [Abstract][Full Text] [Related]
16. Investigations of statins in heart failure: inflammatory biomarkers and hormones.
Khan BV; Rajagopalan S
Heart Fail Clin; 2008 Apr; 4(2):171-6. PubMed ID: 18433697
[TBL] [Abstract][Full Text] [Related]
17. The role of statins in chronic heart failure.
Sadek MM; Haddad T; Haddad H
Curr Opin Cardiol; 2009 Mar; 24(2):167-71. PubMed ID: 19225296
[TBL] [Abstract][Full Text] [Related]
18. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support.
White M; Ducharme A; Ibrahim R; Whittom L; Lavoie J; Guertin MC; Racine N; He Y; Yao G; Rouleau JL; Schiffrin EL; Touyz RM
Clin Sci (Lond); 2006 Apr; 110(4):483-9. PubMed ID: 16402915
[TBL] [Abstract][Full Text] [Related]
19. Inflammation in chronic heart failure.
Parish RC; Evans JD
Ann Pharmacother; 2008 Jul; 42(7):1002-16. PubMed ID: 18477736
[TBL] [Abstract][Full Text] [Related]
20. [Statins in chronic heart failure--new indication?].
Broncel M; Koziróg M; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2006 Jun; 20(120):710-2. PubMed ID: 17007276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
